Giampaolo Merlini

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 357 publications

Selective cellular vulnerability and resilience in amyloidosis: insights from the 2025 International Society of Amyloidosis Workshop.

Selective cellular vulnerability and resilience in amyloidosis: insights from the 2025 International Society of Amyloidosis Workshop.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: August 13, 2026

Guidelines for the management of hereditary ATTR amyloidosis 2026.

Guidelines for the management of hereditary ATTR amyloidosis 2026.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: July 09, 2026

Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)

Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)

Journal: Giornale italiano di cardiologia (2006)

Published: February 03, 2026

A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis.

A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis.

Journal: Blood

Published: December 19, 2025

Reply: Refining Free Light Chain Ratio in Systemic Amyloidosis.

Reply: Refining Free Light Chain Ratio in Systemic Amyloidosis.

Journal: JACC. CardioOncology

Published: December 17, 2025

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Journal: Blood

Published: October 20, 2025

Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

Journal: Blood

Published: October 20, 2025

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Journal: HemaSphere

Published: October 13, 2025

Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.

Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.

Journal: Structure (London, England : 1993)

Published: October 09, 2025

Hepatic response criteria in light chain amyloidosis: a multicenter validation study.

Hepatic response criteria in light chain amyloidosis: a multicenter validation study.

Journal: Haematologica

Published: September 20, 2025

Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.

Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.

Journal: JACC. CardioOncology

Published: September 16, 2025

Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy.

Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy.

Journal: Seminars in hematology

Published: April 19, 2025

Showing 1-12 of 357

Last Updated: 09/26/2026